Authors

Latest:

Emerging Data Supporting the use of Tisagenlecleucel in Patients with R/R Acute Lymphoblastic Leukemia

Led by Dr Armin Ghobadi, the panel reviews data from a study regarding CD19 CAR T-cell therapy use in adults with B-Cell ALL.

Gary J. Schiller, MD, UCLA David Geffen School of Medicine

Gary Kirsh, MD

Latest:

Dr. Kirsh on Advancements in Diagnosing Prostate Cancer

Gary Kirsh, MD, president of The Urology Group and the Large Urology Group Practice Association (LUGPA), discusses advancements in diagnosing patients with prostate cancer.

Gary L. Clayman, DMD, MD, MD Anderson

Gary M. Kirsh, MD, Urology Group

Gary Schwartz, MD

Latest:

Diagnostic Challenges and Clinical Updates in Soft Tissue Sarcomas

Gaudenz Danuser, PhD

Latest:

Dr. Danuser Discusses Impact of RacP29S Mutation in Melanoma

Gaudenz Danuser, PhD, discusses how the activation of RacP29S impacts the treatment of patients with melanoma. His lab has been studying the Rac molecule for around 20 years. The RacP29S mutation most commonly appears in melanoma, but it has since been discovered in a few other cancer types as well.

Gauri R. Varadhachary, MD

Latest:

Radiation Dose Escalation to the Tumor-Arterial Interface of Locally Advanced and Borderline Resectable Pancreatic Cancer

An integrated boost with conventional fractionation to the tumor-arterial interface is unlikely to lead to downstaging in borderline resectable and locally advanced pancreatic cancer.

Gazala N. Khan, MD

Latest:

Dr. Khan on Implications of the REFLECT Trial in HCC

Gazala N. Khan, MD, medical oncologist, Henry Ford Health System, discusses the implications of the REFLECT trial in advanced hepatocellular carcinoma (HCC).

Gennedy Bratslavsky, MD

Latest:

Dr. Bratslavsky on the Evaluation and Management of Kidney Cancer

Gennedy Bratslavsky, MD, deputy director of Upstate Cancer Center, director of the Robotic Program for all Upstate Campuses, and director of the VHL Clinical Cancer Center, discusses the evaluation and management of kidney cancer.

Genovefa Papanicolaou, MD, Memorial Sloan Kettering Cancer Center

Geoffrey Hugo, PhD

Latest:

Diffusion-Weighted MRI Studies Explored at VCU Massey Cancer Center

The Department of Radiation Oncology at Virginia Commonwealth University Massey Cancer Center has long been at the forefront worldwide in the development of various radiation therapy technologies that are now considered standard and have become widely available.

Geoffrey Krampitz, MD

Latest:

Dr. Krampitz on Therapeutic Targets in pNETs

Geoffrey Krampitz, MD, Department of Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, identifies tumorigenic cells and therapeutic targets in patients with pancreatic neuroendocrine tumors.

Geoffrey Lindeman, MD

Latest:

Dr. Lindeman on Rationale for a Phase Ib Trial of Venetoclax and Tamoxifen in Breast Cancer

Geoffrey Lindeman, MD, joint head, Stem Cells and Cancer Division at The Walter and Eliza Hall Institute of Medical Research, discusses a phase 1b dose-escalation and expansion study of the BCL-2 inhibitor venetoclax (Venclexta) combined with tamoxifen in estrogen receptor-positive and BCL-2–positive metastatic breast cancer.

Geoffrey R. Oxnard, MD

Latest:

Dr. Oxnard Discusses RET Fusions in NSCLC

Geoffrey R. Oxnard, MD, associate professor of medicine, Harvard Medical School, thoracic oncologist, Dana-Farber Cancer Institute, discusses RET fusions in non–small cell lung cancer.

Geoffrey R. Oxnard, MD, Harvard

Geoffrey R. Oxnard, MD, Harvard Medical School

Geoffrey Sklar, MD

Latest:

Dr. Sklar on Challenges With Clinical Trials in Bladder Cancer

Geoffrey Sklar, MD, Chief Medical Officer, Chesapeake Urology Associates, discusses some of the challenges that come with conducting clinical trials in the treatment of patients with bladder cancer.

Geoffrey Thomas Gibney, MD, MedStar Georgetown University Hospital

Latest:

Dr. Gibney on the Potential for Fixed-Duration Immunotherapy in Melanoma

Geoffrey T. Gibney, MD, discusses the potential utility of fixed-duration immunotherapy in melanoma.

Geoffrey Uy, MD

Latest:

Dr. Uy on Therapy Selection in Acute Myeloid Leukemia

Geoffrey Uy, MD, assistant professor of medicine, Division of Oncology, Section of Bone Marrow Transplantation, Washington University School of Medicine, Siteman Cancer Center, discusses therapy selection in acute myeloid leukemia (AML).